The breast disease diagnosis and therapy markets are poised for substantial
and sustainable growth, according to this new report from Life Science
Intelligence (LSI). The report, Breast Disease Diagnosis and Therapy Markets,
2007, finds that the $550 million U.S. digital mammography segment is expected
to grow more than 50% annually during the next 3 years as digital technology
replaces analog. In addition, the $167 million US vacuum-assisted biopsy
segment will also experience dramatic growth reaching over $350 million in the
U.S. by 2012. This in-depth report provides a deep and discrete analysis of
the patients, procedures, technologies and companies driving growth and
innovation in the U.S. markets for breast disease diagnosis and therapy.
Non-Interventional Breast Disease Diagnosis - Mammography, computer-aided diagnosis, magnetic resonance imaging, diagnostic ultrasound, screening ultrasound, and various other diagnostic methods.
Interventional Breast Disease Diagnosis - Ultrasound-guided breast biopsy, stereotactic-guided breast biopsy, spring-loaded and vacuum-assisted biopsy techniques, and other methods.
Breast Disease Therapy - Treatment of benign breast disease including surgical intervention, cryoablation, thermoablation, and percutaneous excision. Treatment of malignant breast disease including surgical excision and breast brachytherapy.
Table of Contents
Table of Contents
1. EXECUTIVE SUMMARY
1.2 Disease Incidence
1.3 Non-Interventional Diagnosis
1.3.1 Screening and Diagnostic Mammography
1.3.2 Screening and Diagnostic Ultrasound
1.3.3 Magnetic Resonance Imaging
1.3.4 Other Non-Interventional Modalities
1.4 Interventional Diagnosis
1.5 Breast Therapies and Therapeutic Devices
Exhibit 1.1: Incidence of Breast Cancer (2006-2012E)
Exhibit 1.3: Incidence of Benign Fibroadenomas (2006-2012E)
Exhibit 1.4: Non-Interventional Breast Diagnostic System and Service